Clinical Trial Update: Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy. [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial assessing low-dose pegylated interferon alfa-2b with ribavirin as maintenance therapy for chronic hepatitis C with liver fibrosis in non-respond…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Liver Fibrosis

Drugs mentioned

• Pegylated Interferon Alfa-2b (pegylated interferon alfa-2b)
• Ribavirin (ribavirin)

Snippet

Sponsor: ANRS, Emerging Infectious Diseases | Conditions: Hepatitis C, Chronic, Liver Fibrosis | Phase 2, Phase 3 | Status: COMPLETED